A Study of Oral Piroxicam Compared to Acetaminophen or Placebo for Treating Renal Colic After Emergency Department Care

What this Trial Is About

Renal colic is a common cause of severe abdominal pain leading to many emergency department visits. Researchers are evaluating whether oral non-steroidal anti-inflammatory drugs NSAI, specifically piroxicam, are beneficial as a second line treatment for patients discharged after initial renal colic treatment. This study compares the effects of piroxicam with acetaminophen and placebo to investigate pain recurrence, reconsultation rates, and hospital admissions. Participants are randomly assigned to one of three groups one receives 20 mg of piroxicam daily, another takes 1000 mg of acetaminophen daily, and the third group takes a placebo pill each day. All treatments last for five days. Patients will be contacted by telephone on the seventh day to assess the effectiveness and any side effects experienced. During the study, participants will be monitored through follow-up phone calls to evaluate pain recurrence, safety, and overall treatment impact within seven days. The main outcome measured is the efficacy of the oral NSAI within this one-week period. The study aims to provide clearer guidance on outpatient treatment options for renal colic. The total duration of participation includes the five-day treatment and follow-up contact on day seven.

Oral NSAI Versus Acetaminophen or Placebo as a Discharge Treatment of Non Complicated Renal Colics